Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with MPNs


Disclosures: This work was supported by funding from Novartis Pharmaceuticals; Cancer Center Support Grant/Core Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748); NCI 1K08CA188529-01 (R.K.R); KK12CA087723-14 (G.S.H); NCI R01CA173636 (R.L.L); K99 HL122503-01A1 (M.K.); NIH National Institute of General Medical Sciences Grant T32 GM007739 and NCI F30CA18349 (A.S.M).